Every 8-K that SELLAS Life Sciences Group, Inc. (SLS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SLS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLS filings page.
SELLAS Life Sciences Group, Inc. reported second quarter 2026 results and a corporate update. The late-stage oncology company is advancing its lead programs GPS and SLS009 in acute myeloid leukemia (AML) and exploring SLS009 in solid tumors such as pancreatic ductal adenocarcinoma.
For the quarter ended June 30, 2026, SELLAS recorded a net loss of $9.6 million, or $0.05 per share, compared with a net loss of $6.6 million, or $0.07 per share, a year earlier. Operating expenses rose to $10.6 million from $6.9 million, driven mainly by higher research and development spending to support the Phase 3 REGAL trial of GPS and potential BLA preparation, as well as increased general and administrative costs.
As of June 30, 2026, cash and cash equivalents totaled $138.3 million. The Phase 3 REGAL trial in AML is approaching the pre-specified 80th event that will trigger final efficacy analysis. The Phase 2 SLS009 trial in newly diagnosed AML has enrolled 28 of a planned 80 patients, with topline data expected in the fourth quarter of 2026. Preclinical data suggest SLS009 activity in pancreatic cancer models resistant to RAS inhibitors, with clinical development preparations underway.
SELLAS Life Sciences Group, Inc. estimates unaudited cash and cash equivalents of $138.3 million as of June 30, 2026, subject to completion of financial closing procedures and management review.
The company reports that on July 24, 2026, a sole arbitrator at the Hong Kong International Arbitration Centre dismissed its claims against 3D Medicines, Inc. and allocated approximately $1.0 million of 3D Medicines’ legal fees and costs to be paid by SELLAS. Under an existing exclusive license for galinpepimut-S in the Greater China territory, 3D Medicines announced it will continue development and commercialization, with $191.5 million in potential future milestone payments remaining as of March 31, 2026, including $13.0 million that had been in dispute.
SELLAS Life Sciences Group, Inc. updated executive compensation arrangements related to severance and change of control protection. The company amended CEO Dr. Angelos Stergiou’s employment agreement so that certain change of control severance payments will be made in a lump sum, with all other terms unchanged.
SELLAS also entered into amended and restated severance and change of control letter agreements with CFO John Burns and Chief Development Officer Dr. Dragan Cicic. Outside a change of control, each may receive nine months of base salary, a pro rata target bonus, and up to nine months of COBRA reimbursement if terminated without Cause or resigning for Good Reason. If such a termination occurs within the defined change of control period, each may receive lump sum payments equal to 15 months of base salary, a full target bonus, up to 18 months of COBRA reimbursement, and full vesting of unvested equity awards, subject to signing a separation and general release.
SELLAS Life Sciences Group, Inc. reported the results of its Annual Meeting of Stockholders held on June 16, 2026. A total of 115,511,771 shares, representing approximately 62.59% of outstanding common stock, were present in person or by proxy, establishing a valid quorum.
Stockholders re-elected Class I directors Robert Van Nostrand and Jane Wasman to serve until the 2029 Annual Meeting, ratified Baker Tilly US, LLP as independent auditor for the year ending December 31, 2026, and approved an amendment to the 2023 Equity Incentive Plan to add 20,000,000 shares. They also approved the advisory vote on executive compensation and an adjournment proposal to solicit additional proxies if needed.
SELLAS Life Sciences Group, Inc. provides an update on its cash position and share count. The company had $107.1 million in cash and cash equivalents as of March 31, 2026. In April and May 2026, it received about $28.7 million from the exercise of common stock warrants, adding to its liquidity.
As of June 2, 2026, SELLAS had 196,632,574 shares of common stock outstanding, giving investors a clearer picture of the current capital structure.
SELLAS Life Sciences Group, Inc. reported a first quarter 2026 net loss of $8.4 million, or $0.05 per share, wider than the $5.8 million loss, or $0.07 per share, a year earlier. Higher research and development expenses of $5.1 million and general and administrative expenses of $4.1 million drove the increase as the company invested in clinical programs and regulatory preparation.
Cash and cash equivalents rose to $107.1 million as of March 31, 2026, with an additional $7.5 million received in the second quarter from warrant exercises. SELLAS highlighted progress in its pivotal Phase 3 REGAL trial of GPS in acute myeloid leukemia, with 78 of 80 required events reached as of May 11, 2026, and ongoing dosing in a Phase 2 trial of SLS009 in newly diagnosed AML. The company also put in place an at-the-market equity offering program allowing up to $150 million in future capital raises.
SELLAS Life Sciences Group, Inc. reported a narrower 2025 net loss and a much stronger cash position while advancing its late-stage oncology pipeline. Net loss for 2025 was $26.9 million, or $0.25 per share, compared with $30.9 million, or $0.50 per share, in 2024. Research and development expenses fell to $16.0 million from $19.1 million, mainly after completing enrollment in the Phase 3 REGAL trial of GPS in acute myeloid leukemia. As of December 31, 2025, cash and cash equivalents were $71.8 million, boosted by $67.2 million of 2025 warrant exercise proceeds, with an additional $42.6 million raised from warrant exercises in Q1 2026.
The company is approaching final analysis of the event-driven Phase 3 REGAL study after recording 72 of the required 80 overall-survival events and highlighted positive Phase 2 SLS009 data in relapsed/refractory AML, where overall response was 46% among 35 evaluable patients and median overall survival reached 8.9 months in the least pretreated cohort. SELLAS has begun an 80-patient trial of SLS009 in newly diagnosed AML and entered a European collaboration with IMPACT-AML to study SLS009 with AZA/VEN in about 40 newly diagnosed patients starting in Q2 2026.
SELLAS Life Sciences Group, Inc. reports it has received approximately $42.6 million in cash proceeds from the exercise of common stock warrants subsequent to December 31, 2025. This total includes about $26.5 million received by January 8, 2026 and an additional $16.1 million received after that date.
As of March 11, 2026, the company had 179,536,724 shares of common stock outstanding. The update highlights recent warrant exercises that brought in cash and increased the number of shares held by investors exercising those warrants.
SELLAS Life Sciences Group, Inc. reported that it estimates unaudited cash and cash equivalents of $71.8 million as of December 31, 2025. This figure is preliminary and may change once year-end financial closing procedures and management reviews are completed. After December 31, 2025, the company received approximately $26.5 million in proceeds from the exercise of common stock warrants, adding further liquidity. As of January 7, 2026, SELLAS had 170,282,026 shares of common stock outstanding.
SELLAS Life Sciences Group, Inc. furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025 and a corporate update. The press release is attached as Exhibit 99.1, dated November 12, 2025. The company states the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed filed under the Exchange Act or incorporated by reference into other SEC filings.
SELLAS Life Sciences Group entered a warrant inducement agreement, leading holders to cash exercise previously issued March and August warrants, subject to beneficial ownership limits. The company stated it will receive aggregate gross proceeds of approximately $31.0 million from these exercises before fees and expenses. In return, SELLAS agreed to issue new Inducement Warrants to purchase up to 22,363,714 shares of common stock.
The Inducement Warrants have a $2.00 per share exercise price, are exercisable immediately, and expire five years from issuance. The exercised March and August warrants were exercised at their original exercise prices plus $0.125 per share. SELLAS engaged A.G.P./Alliance Global Partners and Maxim Group LLC as financial advisors and will pay an aggregate fee equal to 5.75% of gross proceeds and reimburse legal expenses up to $60,000.
For 75 days, SELLAS agreed not to issue or register additional equity, with limited exceptions, and for 12 months it is prohibited from entering into any Variable Rate Transaction, including equity lines or at-the-market offerings.
SELLAS Life Sciences Group, Inc. reported a material event on Form 8-K disclosing the company has entered into a Letter Agreement with Times Square Tower Associates LLC. The filing lists Item 1.01 (Entry into a Material Definitive Agreement) and Item 9.01 (Financial Statements and Exhibits) and identifies Exhibit 10.1 as the Letter Agreement. The document record includes an embedded Inline XBRL cover page and is signed by the company’s Senior Vice President, Chief Financial Officer with a reference date in early October 2025. The filing text provided does not specify the Letter Agreement’s commercial terms, purpose, or financial impact.
SELLAS Life Sciences Group, Inc. entered into a warrant inducement agreement with an existing warrant holder to raise cash and restructure its warrant profile. The holder agreed to cash exercise 19,685,040 shares of common stock at $1.20 per share, providing the company with approximately $23.6 million in gross proceeds before fees. In return, SELLAS will issue new inducement warrants to purchase up to 19,685,040 additional shares at an exercise price of $1.88 per share, exercisable immediately and expiring in five and a half years.
The company engaged A.G.P./Alliance Global Partners and Maxim Group as financial advisors and will pay a fee equal to 6.5% of the gross proceeds, plus up to $60,000 in legal expense reimbursement. For 90 days, SELLAS agreed to limit new equity and registration activity with specified exceptions, and for 12 months it is barred from entering variable rate transactions, equity lines, or at-the-market offerings. The new inducement warrants and their underlying shares are being issued in a private, unregistered offering under Section 4(a)(2) of the Securities Act.
SELLAS Life Sciences Group disclosed that it has issued a press release announcing its financial results for the quarter ended June 30, 2025 and providing a corporate update. The press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated by reference, but the company states the press release is furnished and not deemed "filed" for purposes of certain securities laws.
The Form identifies the registrant and trading symbol SLS on Nasdaq, provides principal office contact details, and is signed by John T. Burns, Senior Vice President and Chief Financial Officer. The 8-K itself does not present the underlying financial figures; readers must consult Exhibit 99.1 for complete results and the corporate update.
The Form 8-K filed by SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) discloses the voting results from the Company’s Annual Meeting held on June 17, 2025. Of the 94.5 million shares outstanding, 61.3 million (64.85%) were present or represented by proxy.
- Board elections: Class III directors Angelos M. Stergiou and John Varian were re-elected, receiving 83% and 84% of votes cast, respectively, excluding broker non-votes.
- Auditor ratification: Stockholders confirmed Baker Tilly US, LLP as independent auditor for FY 2025 with a strong 86.9% “For” vote.
- Equity plan amendment: An increase of 800,000 shares under the 2021 Employee Stock Purchase Plan was approved (66% “For”).
- Say-on-pay: The advisory resolution on executive compensation passed with 69% support.
- Say-on-frequency: A plurality of holders (74%) preferred an annual vote on executive compensation.
- Adjournment authority: Shareholders granted the Board discretion to adjourn the meeting if additional proxy solicitation were needed.
No other matters were presented, and no financial performance data or strategic transactions were reported in this filing.